Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 239

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 7
Chunk 239
---
 Indemnification Matters” for information regarding compensation of the members of the Supervisory and Executive Boards.

On December 15, 2023, following Mondher Mahjoubi’s resignation from his position as Chairman of the Executive Board effective December 31, 2023, the Supervisory Board authorized the conclusion of a service agreement with him for the month of January 2024, for compensation equivalent to his monthly fixed salary, i. e., the sum of €39,000

On January 3, 2024, following his appointment as Interim Chairman of the Executive Board, the Supervisory Board authorized the conclusion of a mandate agreement between the Company and Hervé Brailly, which includes the benefit of a French pension contract of €5,503.28.

On January 3, 2024, following his appointment as Chief Operating Officer, member of the Executive Board, the Supervisory Board authorized the entry into of an amendment to an employment contract between the Company and Yannis Morel, which includes, a fixed annual remuneration of €300,000 and a French pension contract of €5,662.02.

On January 3, 2024, following her appointment as a member of the Executive Board, the Supervisory Board authorized the entry into of an amendment to an employment contract between the Company and Sonia Quaratino, which includes an individual bonus of 40% based on reaching certain specified targets, rising to 60% in the event of outperformance.

On October 11, 2024, the Supervisory Board authorized the conclusion of a consulting agreement with Addexpert and then, after expiration of that agreement, with Kervrant Biotech, a company wholly owned by Hervé Brailly, to continue the consulting and support services for the new Chairman of the Executive Board during the transition period, until May 31, 2025, at the latest, for a maximum amount of 10,000 € a month, depending on time spent.

On June 1, 2024, the Supervisory Board authorized the conclusion of a consulting agreement with Ariana Pharmaceuticals, a company in which Véronique Chabernaud is acting CMO and Jean-Yves Blay is a scientific advisor, aimed at using artificial intelligence to accelerate the development of the Company's products.

On May 12, 2023, the Supervisory Board authorized the conclusion of an agreement between Innate Pharma and Jean-Yves Blay in his capacity as a member of the